|
KMID : 1143120140040020129
|
|
Asia Pacific Allergy
2014 Volume.4 No. 2 p.129 ~ p.130
|
|
|
Omalizumab in recurring larynx angioedema: a case report
|
|
Ozturk Ayse Bilge
Kocaturk Emek
|
|
|
Abstract
|
|
|
|
Angioedema with swelling of larynx is a serious allergic reaction and can be life-threatening. It can occur after exposure to various triggers and usually it is very difficult for the patient and the doctor to find the trigger and maintain complete remission. In idiopathic recurring angioedema presenting with frequent attacks, prophylaxis with H1 antihistamines recommended. However, not all patients respond to antihistamines. Omalizumab is an anti-immunoglobulin (Ig)-E-Ig-G antibody approved for the treatment of asthma and also effective treatment in chronic spontaneous urticaria. We report a 47-year-old male patient with severe idiopathic angioedema controlled by corticosteroid and proggressed after discontining of corticosteroid because of its side effects. Omalizumab at a dose of 300 mg every 4 weeks was administrated and omalizumab provided a rapid clinical response after first injection. During the 4 months of omalizumab therapy, he had no further attacks and any other treatment needs. After 3 months of stopping omalizumab therapy, during the 4-week period he had two mild lip swelling in his lips that resolved with antihistamines.
|
|
|
KEYWORD
|
|
|
Omalizumab, Angioedema, Larynx
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|